IMPORTANT-New Recommendations on the Use of COVID-19 Monovalent Novavax Vaccine as a Booster

Dear Immunization Partners,

On October 19, 2022, the Centers for Disease Control and Prevention (CDC) provided guidance on the newly amended Emergency Use Authorization (EUA) for the COVID-19 monovalent Novavax vaccine for use as a booster dose. The Interim Clinical Considerations were updated to include the recommendations as follows:

• Guidance for use of a monovalent Novavax COVID-19 booster dose in people ages 18 years and older in limited situations:
  • If unable to receive an mRNA vaccine as a result of an allergy to a component of an mRNA COVID-19 vaccine.
  • If unable to receive an mRNA COVID-19 vaccine as a result of a history of a severe allergic reaction (such as anaphylaxis) after a previous dose of an mRNA COVID-19 vaccine.
  • If there is a lack of availability of an mRNA vaccine.
  • May also choose to receive a Novavax monovalent booster if they are unwilling to receive mRNA vaccines and would otherwise not receive a booster dose.

• Spacing of booster dose, if eligible under above limited situations:
  • People ages 18 years and older who completed primary vaccination using any COVID-19 vaccine and have not received any previous booster dose(s) may receive a monovalent Novavax booster dose at least 6 months after completion of the primary series.

Updated information has been published as of October 19, 2022, or soon thereafter:

• EUA Fact Sheet for Healthcare Providers
• Vaccines.gov  
• COVID-19 booster tool  
• Stay Up to Date with COVID-19 Vaccines Including Boosters | CDC

If you have additional questions, please contact checcimms@michigan.gov. 

Thank you for all you do to protect Michiganders against COVID-19. 

Oakland County Health Division, Immunization Action Plan